{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:26:41Z","timestamp":1782937601956,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00417-015-3198-5","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T02:54:35Z","timestamp":1445914475000},"page":"2279-2284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener\u2019s)"],"prefix":"10.1007","volume":"253","author":[{"given":"Claudia","family":"Recillas-Gispert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Serna-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0172-8023","authenticated-orcid":false,"given":"Luis Felipe","family":"Flores-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"3198_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12177-009-9044-4","volume":"3","author":"AS Watkins","year":"2009","unstructured":"Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C et al (2009) Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor 3:12\u201319","journal-title":"J Ocul Biol Dis Infor"},{"key":"3198_CR2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1196\/annals.1381.042","volume":"1107","author":"LF Flores-Su\u00e1rez","year":"2007","unstructured":"Flores-Su\u00e1rez LF, Villa AR (2007) Spectrum of Wegener granulomatosis in a Mexican population. Ann N Y Acad Sci 1107:400\u2013409","journal-title":"Ann N Y Acad Sci"},{"key":"3198_CR3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","volume":"44","author":"U Specks","year":"2001","unstructured":"Specks U, Fervenza FC, McDonald TJ, Hogan MC (2001) Response of Wegener\u2019s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836\u20132840","journal-title":"Arthritis Rheum"},{"key":"3198_CR4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"3198_CR5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","volume":"33","author":"RY Leavitt","year":"1990","unstructured":"Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis. Arthritis Rheum 33:1101\u20131107","journal-title":"Arthritis Rheum"},{"key":"3198_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187\u2013192","journal-title":"Arthritis Rheum"},{"key":"3198_CR7","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"3198_CR8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605\u2013617","journal-title":"Ann Rheum Dis"},{"key":"3198_CR9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"PM Aries","year":"2006","unstructured":"Aries PM, Hellmich B, Voswinkel J et al (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853\u2013858","journal-title":"Ann Rheum Dis"},{"key":"3198_CR10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/keh300","volume":"43","author":"PM Aries","year":"2004","unstructured":"Aries PM, Hellmich B, Reinhold-Keller E, Gross WL (2004) High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology (Oxford) 43:1307\u20131308","journal-title":"Rheumatology (Oxford)"},{"key":"3198_CR11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","volume":"60","author":"SR Taylor","year":"2009","unstructured":"Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 60:1540\u20131547","journal-title":"Arthritis Rheum"},{"key":"3198_CR12","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.ophtha.2011.06.009","volume":"118","author":"L Joshi","year":"2011","unstructured":"Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR (2011) Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 118:2498\u20132503","journal-title":"Ophthalmology"},{"key":"3198_CR13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","volume":"122","author":"L Joshi","year":"2015","unstructured":"Joshi L, Tanna A, McAdoo SP et al (2015) Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease. Ophthalmology 122:1262\u20131268","journal-title":"Ophthalmology"},{"key":"3198_CR14","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60:2156\u20132168","journal-title":"Arthritis Rheum"},{"key":"3198_CR15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262\u2013268","journal-title":"Arthritis Rheum"},{"key":"3198_CR16","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64:3770\u20133778","journal-title":"Arthritis Rheum"},{"key":"3198_CR17","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","volume":"65","author":"EM Miloslavsky","year":"2013","unstructured":"Miloslavsky EM, Specks U, Merkel PA et al (2013) Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65:2441\u20132449","journal-title":"Arthritis Rheum"},{"key":"3198_CR18","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","volume":"53","author":"E Besada","year":"2014","unstructured":"Besada E, Koldingsnes W, Nossent JC (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 53:1818\u20131824","journal-title":"Rheumatology (Oxford)"},{"key":"3198_CR19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ICO.0b013e3181c296ed","volume":"29","author":"V Huerva","year":"2010","unstructured":"Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A (2010) Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea 29:708\u2013710","journal-title":"Cornea"},{"key":"3198_CR20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","volume":"121","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM et al (2014) Rituximab therapy for refractory scleritis: results of a phase I\/II dose ranging, randomized, clinical trial. Ophthalmology 121:1885\u20131891","journal-title":"Ophthalmology"},{"key":"3198_CR21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","volume":"85","author":"F Zaja","year":"2010","unstructured":"Zaja F, Vianelli N, Volpetti S et al (2010) Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 85:329\u2013334","journal-title":"Eur J Haematol"},{"key":"3198_CR22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.12102","volume":"90","author":"D G\u00f3mez-Almaguer","year":"2013","unstructured":"G\u00f3mez-Almaguer D, Tar\u00edn-Arzaga L, Moreno-Jaime B, Jaime-P\u00e9rez JC, Ceballos-L\u00f3pez AA, Ruiz-Arg\u00fcelles GJ et al (2013) High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 90:494\u2013500","journal-title":"Eur J Haematol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-015-3198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-015-3198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-015-3198-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:56Z","timestamp":1559058056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-015-3198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3198"],"URL":"https:\/\/doi.org\/10.1007\/s00417-015-3198-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]}}}